Ardelyx, Inc. (ARDX) – What Are Brokerages Saying About This Stock?

Posted by Francis Steltz on Oct 25th, 2026

Shares of Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $13.90.

Several brokerages have recently issued reports on ARDX. Zacks Research upgraded shares of Ardelyx from a “strong sell” rating to a “hold” rating in a research note on Friday, October 16th. Citigroup decreased their price objective on Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Wedbush reiterated an “outperform” rating and set a $9.00 target price on shares of Ardelyx in a research report on Tuesday, August 18th. Piper Sandler decreased their price objective on Ardelyx from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Monday, August 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Ardelyx in a report on Friday, August 7th.

View Our Latest Analysis on ARDX

Ardelyx News Summary

Here are the key news stories impacting Ardelyx this week:

Positive Sentiment: Real-world data presented at ASN Kidney Week 2026 showed serum-phosphate reductions after initiating XPHOZAH (tenapanor), including among patients using different phosphate-binder regimens. The findings support XPHOZAH’s effectiveness in routine clinical practice and could help its commercial adoption. Ardelyx Presents Real-World Data at ASN Kidney Week 2026
Positive Sentiment: Piper Sandler reaffirmed its Buy rating, providing continued sell-side support for Ardelyx’s outlook. Piper Sandler Reaffirms Buy Rating

Insider Buying and Selling at Ardelyx

In other Ardelyx news, insider Eric Foster sold 8,562 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $33,049.32. Following the transaction, the insider owned 409,410 shares of the company’s stock, valued at approximately $1,580,322.60. The trade was a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Raab sold 58,574 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $226,095.64. Following the completion of the transaction, the chief executive officer directly owned 1,619,792 shares of the company’s stock, valued at approximately $6,252,397.12. This represents a 3.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 126,059 shares of company stock worth $486,588 over the last 90 days. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new position in Ardelyx during the second quarter valued at approximately $119,874,000. Jupiter Topco LLC acquired a new stake in Ardelyx during the 2nd quarter worth approximately $27,043,000. AIGH Capital Management LLC acquired a new position in shares of Ardelyx in the second quarter valued at approximately $16,320,000. Bank of America Corp DE increased its position in shares of Ardelyx by 5.8% during the first quarter. Bank of America Corp DE now owns 2,336,994 shares of the biopharmaceutical company’s stock worth $13,999,000 after acquiring an additional 128,301 shares in the last quarter. Finally, Eversept Partners LP grew its holdings in shares of Ardelyx by 30.0% during the first quarter. Eversept Partners LP now owns 2,229,446 shares of the biopharmaceutical company’s stock worth $13,354,000 after buying an additional 514,317 shares in the last quarter. Institutional investors and hedge funds own 58.92% of the company’s stock.

Ardelyx Stock Performance

ARDX stock opened at $3.08 on Friday. The company has a market capitalization of $767.51 million, a price-to-earnings ratio of -14.00 and a beta of 0.68. The firm has a 50 day moving average of $3.52 and a two-hundred day moving average of $4.91. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.69. Ardelyx has a 12 month low of $3.02 and a 12 month high of $8.40.

Ardelyx (NASDAQ:ARDX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $120.88 million during the quarter, compared to the consensus estimate of $121.03 million. Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The firm’s revenue was up 34.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.08) earnings per share. As a group, equities analysts anticipate that Ardelyx will post -0.20 EPS for the current fiscal year.

Ardelyx Company Profile

(Get Free Report)

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.